MOVES

and telecom sector, before judicial forums in India and institutional and ad hoc arbitral tribunals. Besides arbitrations, Chaturvedi has acted for clients in commercial and white-collar crime litigation, and bankruptcy matters, and has represented them before various judicial forums. Beyond commercial dispute representation, he has advised clients on contractual claims, BITs executed by the Government of India and dispute resolution procedures before arbitration tribunals. Chaturvedi is a 2009 graduate of Symbiosis Law School, Pune. He also pursued an LLM in International Dispute Settlement from the University of Geneva and the Graduate Institute of International & Development Studies in 2015-16, where he focused on commercial and investment arbitration and Public International Law.

Baker McKenzie has added leading FDA regulatory lawyer Xin Tao as a partner in Washington, DC, joining the firm’s growing food and drug regulatory team, and bringing scientific background, deep experience in food technology and East Asia. For more than a decade, Tao has advised companies on how to navigate evolving regulatory environments with innovative legal strategies that support their commercialisation of consumer products made with emerging technologies. His practice focuses on novel food and drug applications that require FDA review and FDA Current Good Manufacturing Practices (cGMP) compliance. Tao has extensive experience advising food technology companies and investors on developing and marketing innovative products, including cell-cultured meat protein derived from microbial fermentation and bioengineering. A former research biochemist, he brings a deep understanding of the complex scientific issues that relate to the FDA’s legal and regulatory requirements, enabling him to help clients with all phases of product development, manufacturing and marketing. Leveraging his scientific background, he has also worked extensively on FDA enforcement actions and consumer class action litigation involving environmental contaminants in foods, such as heavy metals, PFAS, and California’s Proposition 65- listed chemicals. Born and raised in China, Tao is also wellequipped to assist global companies in adapting to the evolving regulatory regime of China’s National Medical Products Administration (NMPA), formerly known as China Food and Drug Administration (CFDA). In addition to US-based clients, he has also worked extensively with Chinese and Japanese food and pharmaceutical companies. He earned his BS in Biotechnology from Shanghai Jiao Tong University, his MS in Biochemistry from Texas A&M, and his JD from Georgetown University Law Center.

Shanghai Lang Yue Law Firm (Lang Yue), Allen & Overy’s joint operation partner, will add Vivian Cao, an experienced antitrust and competition law specialist, as a partner to further strengthen the firm’s China antitrust capacity, and support the growth of the regulatory compliance and litigation practices. Cao advises multinational and Chinese clients on a wide range of international and domestic merger control and behavioural antitrust matters. She has also worked on a number of high-profile global transactions from the early stages of China antitrust